Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $0.64 in the prior trading day, Sangamo Therapeutics Inc (NASDAQ: SGMO) closed at $0.64, down -0.87%. In other words, the price has decreased by -$0.87 from its previous closing price. On the day, 5.01 million shares were traded. SGMO stock price reached its highest trading level at $0.65 during the session, while it also had its lowest trading level at $0.6114.
Ratios:
Our goal is to gain a better understanding of SGMO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.05 and its Current Ratio is at 1.05. In the meantime, Its Debt-to-Equity ratio is 1.20 whereas as Long-Term Debt/Eq ratio is at 1.20.
On December 10, 2024, H.C. Wainwright reiterated its Buy ratingand also kept the price unchanged to $10.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 03, 2023, whereas the target price for the stock was revised from $6 to $2.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 192882864 and an Enterprise Value of 177999872. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.36 while its Price-to-Book (P/B) ratio in mrq is 8.90. Its current Enterprise Value per Revenue stands at 2.179 whereas that against EBITDA is -3.055.
Stock Price History:
The Beta on a monthly basis for SGMO is 1.28, which has changed by -0.29670328 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $3.18, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is 9.44%, while the 200-Day Moving Average is calculated to be -11.66%.
Shares Statistics:
The stock has traded on average 5.84M shares per day over the past 3-months and 4893700 shares per day over the last 10 days, according to various share statistics. A total of 301.71M shares are outstanding, with a floating share count of 291.31M. Insiders hold about 3.44% of the company’s shares, while institutions hold 17.22% stake in the company. Shares short for SGMO as of 1759190400 were 18829925 with a Short Ratio of 3.23, compared to 1756425600 on 14978395. Therefore, it implies a Short% of Shares Outstanding of 18829925 and a Short% of Float of 6.3.
Earnings Estimates
. The current rating of Sangamo Therapeutics Inc (SGMO) reflects the combined expertise of 3 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.07 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.37 and -$0.43 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.3, with 3.0 analysts recommending between -$0.12 and -$0.4.
Revenue Estimates
5 analysts predict $34.4M in revenue for. The current quarter. It ranges from a high estimate of $100M to a low estimate of $4M. As of. The current estimate, Sangamo Therapeutics Inc’s year-ago sales were $49.41M
A total of 5 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $124.7M, while the lowest revenue estimate was $34.7M, resulting in an average revenue estimate of $72.3M. In the same quarter a year ago, actual revenue was $57.8MBased on 5 analysts’ estimates, the company’s revenue will be $48.3M in the next fiscal year. The high estimate is $114.2M and the low estimate is $8.6M.
